113 related articles for article (PubMed ID: 36842751)
1. The effects of epirubicin-loaded Boc-L-Diphenylalanine peptide nanoparticles on cytotoxicity, genotoxicity, oxidative stress, and apoptosis in non-small cell lung cancer cells.
Altuntas S
Food Chem Toxicol; 2023 May; 175():113690. PubMed ID: 36842751
[TBL] [Abstract][Full Text] [Related]
2. Epirubicin loaded to pre-polymerized poly(butyl cyanoacrylate) nanoparticles: preparation and in vitro evaluation in human lung adenocarcinoma cells.
Yordanov G; Evangelatov A; Skrobanska R
Colloids Surf B Biointerfaces; 2013 Jul; 107():115-23. PubMed ID: 23466549
[TBL] [Abstract][Full Text] [Related]
3. Improved antitumor activity of epirubicin-loaded CXCR4-targeted polymeric nanoparticles in liver cancers.
Di-Wen S; Pan GZ; Hao L; Zhang J; Xue QZ; Wang P; Yuan QZ
Int J Pharm; 2016 Mar; 500(1-2):54-61. PubMed ID: 26748365
[TBL] [Abstract][Full Text] [Related]
4. RPV-modified epirubicin and dioscin co-delivery liposomes suppress non-small cell lung cancer growth by limiting nutrition supply.
Kong L; Cai FY; Yao XM; Jing M; Fu M; Liu JJ; He SY; Zhang L; Liu XZ; Ju RJ; Li XT
Cancer Sci; 2020 Feb; 111(2):621-636. PubMed ID: 31777993
[TBL] [Abstract][Full Text] [Related]
5. Epirubicin loading in poly(butyl cyanoacrylate) nanoparticles manifests via altered intracellular localization and cellular response in cervical carcinoma (HeLa) cells.
Evangelatov A; Skrobanska R; Mladenov N; Petkova M; Yordanov G; Pankov R
Drug Deliv; 2016 Sep; 23(7):2235-2244. PubMed ID: 25268149
[TBL] [Abstract][Full Text] [Related]
6. RGD-peptide conjugated inulin-ibuprofen nanoparticles for targeted delivery of Epirubicin.
Zhang L; Li G; Gao M; Liu X; Ji B; Hua R; Zhou Y; Yang Y
Colloids Surf B Biointerfaces; 2016 Aug; 144():81-89. PubMed ID: 27070055
[TBL] [Abstract][Full Text] [Related]
7. Targeted delivery of vitamin D3-loaded nanoparticles to C6 glioma cell line increased resistance to doxorubicin, epirubicin, and docetaxel in vitro.
Maleklou N; Allameh A; Kazemi B
In Vitro Cell Dev Biol Anim; 2016 Dec; 52(10):989-1000. PubMed ID: 27503515
[TBL] [Abstract][Full Text] [Related]
8. Development of R
Liu JJ; Tang W; Fu M; Gong XQ; Kong L; Yao XM; Jing M; Cai FY; Li XT; Ju RJ
Artif Cells Nanomed Biotechnol; 2019 Dec; 47(1):1947-1960. PubMed ID: 31079495
[TBL] [Abstract][Full Text] [Related]
9. Solamargine upregulation of Fas, downregulation of HER2, and enhancement of cytotoxicity using epirubicin in NSCLC cells.
Liang CH; Shiu LY; Chang LC; Sheu HM; Kuo KW
Mol Nutr Food Res; 2007 Aug; 51(8):999-1005. PubMed ID: 17639997
[TBL] [Abstract][Full Text] [Related]
10. Improved antitumor activity and reduced cardiotoxicity of epirubicin using hepatocyte-targeted nanoparticles combined with tocotrienols against hepatocellular carcinoma in mice.
Nasr M; Nafee N; Saad H; Kazem A
Eur J Pharm Biopharm; 2014 Sep; 88(1):216-25. PubMed ID: 24813390
[TBL] [Abstract][Full Text] [Related]
11. Entrapment of epirubicin in poly(butyl cyanoacrylate) colloidal nanospheres by nanoprecipitation: formulation development and in vitro studies on cancer cell lines.
Yordanov G; Skrobanska R; Evangelatov A
Colloids Surf B Biointerfaces; 2012 Apr; 92():98-105. PubMed ID: 22154011
[TBL] [Abstract][Full Text] [Related]
12. Folic acid (FA)-conjugated mesoporous silica nanoparticles combined with MRP-1 siRNA improves the suppressive effects of myricetin on non-small cell lung cancer (NSCLC).
Song Y; Zhou B; Du X; Wang Y; Zhang J; Ai Y; Xia Z; Zhao G
Biomed Pharmacother; 2020 May; 125():109561. PubMed ID: 32106385
[TBL] [Abstract][Full Text] [Related]
13. Surface functionalized mesoporous silica nanoparticles as an effective carrier for epirubicin delivery to cancer cells.
Hanafi-Bojd MY; Jaafari MR; Ramezanian N; Xue M; Amin M; Shahtahmassebi N; Malaekeh-Nikouei B
Eur J Pharm Biopharm; 2015 Jan; 89():248-58. PubMed ID: 25511563
[TBL] [Abstract][Full Text] [Related]
14. Bevacizumab and CCR2 Inhibitor Nanoparticles Induce Cytotoxicity-Mediated Apoptosis in Doxorubicin-Treated Hepatic and Non-Small Lung Cancer Cells.
Abd-Rabou AA; Ahmed HH
Asian Pac J Cancer Prev; 2019 Jul; 20(7):2225-2238. PubMed ID: 31350989
[TBL] [Abstract][Full Text] [Related]
15. Overexpression of miR-4443 promotes the resistance of non-small cell lung cancer cells to epirubicin by targeting INPP4A and regulating the activation of JAK2/STAT3 pathway.
Zhang W; Qiao B; Fan J
Pharmazie; 2018 Jul; 73(7):386-392. PubMed ID: 30001772
[TBL] [Abstract][Full Text] [Related]
16. Phase II study of high-dose epirubicin in non-small cell lung cancer.
Wils J; Utama I; Sala L; Smeets J; Riva A
Eur J Cancer; 1990; 26(11-12):1140-1. PubMed ID: 1963545
[TBL] [Abstract][Full Text] [Related]
17. Twin-Arginine Translocation Peptide Conjugated Epirubicin-Loaded Nanoparticles for Enhanced Tumor Penetrating and Targeting.
Zhang L; Liu F; Li G; Zhou Y; Yang Y
J Pharm Sci; 2015 Dec; 104(12):4185-4196. PubMed ID: 26398477
[TBL] [Abstract][Full Text] [Related]
18. Solamargine enhances HER2 expression and increases the susceptibility of human lung cancer H661 and H69 cells to trastuzumab and epirubicin.
Liang CH; Shiu LY; Chang LC; Sheu HM; Tsai EM; Kuo KW
Chem Res Toxicol; 2008 Feb; 21(2):393-9. PubMed ID: 18078328
[TBL] [Abstract][Full Text] [Related]
19. Application of multifunctional targeting epirubicin liposomes in the treatment of non-small-cell lung cancer.
Song XL; Ju RJ; Xiao Y; Wang X; Liu S; Fu M; Liu JJ; Gu LY; Li XT; Cheng L
Int J Nanomedicine; 2017; 12():7433-7451. PubMed ID: 29066893
[TBL] [Abstract][Full Text] [Related]
20. Progesterone augments epirubicin-induced apoptosis in HA22T/VGH cells by increasing oxidative stress and upregulating Fas/FasL.
Chang WT; Hsieh BS; Cheng HL; Lee KT; Chang KL
J Surg Res; 2014 May; 188(2):432-41. PubMed ID: 24594218
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
